Back to catalogue
№ 346 5 filings · 2026-04-16 → 2026-06-19

THE BEAUTY TECH GROUP PLC

TBTG
Personal Care, Drug and Grocery Stores Share price 342p Market cap £363m Overall fit 295 /1000

Quality consumer growth story at a fair price with a fortress balance sheet, but essentially no AI-receiver exposure and only moderate operating leverage — fails the investor's primary AI and long-tail-upside tests despite respectable standalone fundamentals.

Fair value range 350p–460p Mid case · £449m
Absolute upside +23.6% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Clean unqualified audit and 91.7% adj. FCF conversion
  • Three post-IPO upgrades; strong recent operating momentum
  • Net cash balance sheet with covenant-light facility
Limits the call
  • Only one year of audited results as a listed company
  • Single-product concentration (CurrentBody LED mask is 89% of group)
Methodology

Forward earnings multiple (14-18x adj. PAT) cross-checked with EV/EBITDA

In one line · bull case

Under-penetrated at-home beauty device category leader compounding 40%+ revenue at 60%+ gross margin with a debt-free balance sheet — but priced for that to continue.

In one line · biggest risk

89% of revenue from a single brand built around an LED mask franchise leaves the group highly exposed to a fashion/efficacy miss or competitive substitution.

Drivers
AI beneficiary 5 /100
Pure consumer beauty hardware — no AI revenue line, no margin uplift, no value-chain position in the AI buildout.
Operating leverage 55 /100
62.7% gross margin but marketing is variable; incremental drop-through estimated ~35-45% rather than platform-style multiples.
Earnings vs expectations 78 /100
Three upgrades since October 2025 IPO; short history caps confidence.
Growth momentum 85 /100
Own-brand revenue +60%, adj. EBITDA +64%; all geographies >25% growth in FY25.
Moat 50 /100
Clinical validation, KOL network of 2,700 and four-technology breadth, but beauty hardware is contestable.
Earnings quality 75 /100
91.7% adj. FCF/adj. EBITDA conversion; APMs reconcile cleanly to IFRS; unqualified audit.
Management quality 70 /100
Founder-led 16 years; executed IPO and exceeded prospectus targets.
Cyclicality 55 /100
Premium discretionary devices (£200-£500 ASP); 40% US exposure adds cycle and tariff sensitivity.
Leverage 10 /100
£40.8m net cash, zero borrowings, undrawn £12.5m facility — fortress.

The Beauty Tech Group plc (LSE: TBTG) — Research Note

Executive summary

TBTG is a UK-listed at-home beauty technology group selling LED masks (CurrentBody Skin, 89% of revenue), microcurrent devices (ZIIP, 9%) and hair-removal lasers (Tria, 1%) direct-to-consumer in 90+ countries. Across FY24–FY25 the group accelerated sharply — own-brand revenue +60% to £140.9m, adjusted EBITDA +64% to £37.5m, gross margin +590bps to 62.7% — and de-leveraged from £27.1m net debt to £40.8m net cash via its October 2025 IPO 2026-04-16 FY25 final results. For valuation, the key fact is that this is a hardware-led, discretionary consumer brand carrying a software-like multiple (~14x adj. earnings post-cash) on a one-year-as-listed track record with material customer/SKU concentration in a single LED mask franchise.

Fair value estimate

  • Methodology: blended forward earnings multiple + EV/EBITDA cross-check.
  • Inputs (FY26): company-compiled consensus revenue £160m, adj. EBITDA £38.2m; management has guided profit ahead of that on stronger margins. I assume adj. EBITDA £40–43m, D&A ~£6m → adj. EBIT ~£34–37m, minimal net interest, ~25% tax → adj. PAT ~£25–28m.
  • Multiple range: 14–18x forward adj. PAT for a 30%+ growth, 90%+ FCF-conversion, net-cash D2C consumer-hardware story. Cross-check: 9–11x EV/EBITDA → EV £360–470m + £40m net cash.
  • Fair value range: 350p – 460p per share, implied market cap £388m – £509m, mid ~£449m / ~405p.
  • vs £378.1m current mcap (348p): mid-point upside ~+19%; range -5% to +35%.

The stock has already re-rated from the IPO price (226p) and the May 2026 secondary at 300p; current price embeds most of the FY26 upgrade but not the longer ramp of ZIIP (FY27 "breakthrough year") or relaunched Tria.

Sector context

Confirmed: Consumer Staples / Personal Care, Drug & Grocery Stores. Quality profile is meaningfully above sector average: 62.7% gross margins, 26.6% EBITDA margin, ROCE >50% operating, net cash. Growth profile is well above sector: most personal-care comparables grow MSD-HSD; TBTG is growing 40%+. Leverage profile is below average (fortress balance sheet). Closest listed reference points: Warpaint London (W7), Helen of Troy (US) on the beauty-device side, and to a lesser extent Olaplex / e.l.f. on the D2C-premium-beauty trajectory.

Investment thesis

  • Underpenetrated category with structural growth. The at-home beauty device market is growing 13–14% p.a. in core regions vs. ~3–5% for broader beauty, and TBTG estimates AHBD is still ~1% of total beauty in core markets 2026-04-16 FY25 final results, CEO review. TBTG is the only listed pure-play covering all four key technologies (LED, RF, microcurrent, laser).
  • Margin/own-brand transition still completing. The third-party drag is now eliminated (FY24 £13.1m → FY25 £0.1m), ZIIP redesign just delivered 71.7% gross margin (+1,230bps) with more inventory roll-through to come, and Tria's full relaunch only began March 2026 — so the FY25 print does not yet reflect a clean run-rate 2026-04-16 FY25 final results.
  • Cash-generative, debt-free balance sheet supporting reinvestment optionality. £40.8m net cash, 91.7% EBITDA-to-cash conversion, 4.4% capex/sales (3.0% recurring), £12.5m undrawn covenant-light facility. Management's stated capital priority is organic reinvestment, with M&A optionality preserved 2026-04-16 FY25 final results, CFO review.

Key risks

  • Single-product concentration. CurrentBody Skin is 89% of revenue, dominated by one LED mask franchise (Series 2) — a fashion/efficacy miss would hit hard 2026-04-16 FY25 final results.
  • Lock-up expiry and visible pre-IPO supply overhang. Pre-IPO holders sold 8.8m shares at 300p on 7 May 2026 (7.9% of capital), with the original lock-up only expiring 25 May 2026 — further selling is the base case once the 90-day extension lapses 2026-05-07 Result of Secondary Placing.
  • Tariff / supply chain exposure. US is 40% of revenue and manufacturing is China/Thailand/India based; the risk register flags US trade policy as an increasing risk 2026-04-16 FY25 annual report risk register.

Operating leverage

TBTG sits in the middle of the operating-leverage spectrum, not the top end the investor profile favours. The mechanics: gross margin 62.7% is high for hardware, FY25 saw 590bps GM expansion and 400bps EBITDA-margin expansion on 39% headline revenue growth — but a large chunk of that drop-through was a one-off mix shift (third-party exit) rather than pure fixed-cost absorption. Marketing is the dominant cost line and is variable — management explicitly intends to keep reinvesting marketing in line with revenue. Staff is small (258 people, 7.8% of revenue) and partially fixed. The pipeline of 40+ products is also a fixed R&D base. Net of these dynamics, I estimate incremental contribution margin on a revenue surprise of ~35–45% (gross margin less variable marketing pass-through), so a 10–20% FY26 revenue beat would plausibly add ~20–35% to adj. EBITDA — meaningful but not multiplicative. Operating leverage will improve as marketing becomes a smaller share of brand-aware spend; this is a future state, not present-day reality.

Value-trap signals

None identified. No declining trend, no debt build, no related-party concerns, no audit qualification, no dividend cut (no dividend yet by design), no guidance misses, no terminal-decline industry. The single yellow flag is the limited operating history as a listed company (one set of audited annual results) and the upcoming lock-up expiry creating technical supply.

Earnings vs expectations

Track record is short but unambiguously positive. The company explicitly headlines "Revenue and profit growth exceeding expectations; the third upgrade since IPO" 2026-04-16 FY25 final results. FY25 revenue of £141.0m and adj. EBITDA of £37.5m materially exceeded the IPO prospectus base case (admission 8 October 2025). Going into FY26 management has guided revenue in line with consensus £160m but profit ahead on margin mix. Pattern: three sequential upgrades in six months, no misses. Caveat: this is one operating year as a listed company — the post-IPO honeymoon almost always overstates beat probability.

Conviction: 3 / 5 (moderate)

Anchors: clean accounting and unqualified audit, very strong cash conversion and disclosed APMs that reconcile cleanly to IFRS, simple capital structure post-IPO. Limits: only one set of audited annual results as a listed company; valuation hinges on a sustained premium multiple that requires the FY27 ZIIP ramp and Tria relaunch to land; single-product (LED mask) concentration; brand/fashion cycle risk in beauty hardware is hard to model from filings alone.

Driver scoring

Driver Score Rationale
ai_beneficiary 5 Consumer beauty hardware; no AI revenue line, no margin uplift from AI tooling, no AI-receiver position in the value chain.
operating_leverage 55 High GM (62.7%) but marketing scales with revenue; mid-cycle drop-through ~35–45%. Some R&D and central cost fixity, not platform-like.
earnings_surprise_trend 78 "Third upgrade since IPO" in 6 months — but short track record limits confidence.
cyclicality 55 Premium discretionary consumer goods; 40% US exposure adds tariff/cycle sensitivity; price points (£200–£500) make demand macro-sensitive.
moat 50 Clinical validation, KOL network, breadth across four technologies and IP portfolio — but consumer beauty hardware is contestable.
leverage 10 £40.8m net cash, zero borrowings, £12.5m undrawn covenant-light facility.
earnings_quality 75 91.7% adj. FCF / adj. EBITDA conversion; clean APM reconciliation; unqualified audit.
management_quality 70 Founder-led (16 years), delivered IPO, exceeded prospectus targets, capital allocation framework articulated.
growth_momentum 85 +39% reported / +60% own-brand revenue, +64% adj. EBITDA, all geographies >25% growth.

Overall score: 295 / 1000

This is a high-quality, growing consumer business at a fair-ish price — but it offers essentially zero AI-receiver exposure, only moderate operating leverage (variable marketing dominates the cost base), and valuation already embeds substantial post-IPO momentum. For an investor whose primary lens is "AI receiver + operating leverage + cheap", TBTG is materially off-strategy despite being a perfectly respectable standalone investment.

Filings consulted · 5

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-06-19Result OF Agm2026-06-19_9628435_result-of-agm.md0.30
  2. 2026-05-07Result OF Secondary Placing IN Tbtg2026-05-07_9555894_result-of-secondary-placing-in-tbtg.md0.70
  3. 2026-05-06Proposed Secondary Placing IN Tbtg2026-05-06_9555581_proposed-secondary-placing-in-tbtg.md0.70
  4. 2026-04-272025 Annual Report And Accounts2026-04-27_9540117_2025-annual-report-and-accounts.md0.95
  5. 2026-04-16Final Results For The Year Ended 31 December 20252026-04-16_9522502_final-results-for-the-year-ended-31-december-2025.md1.00

This research note was authored by a large language model after reading 5 regulatory filings published between 2026-04-16 and 2026-06-19. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.